Clinical Trial Search

Primary: Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month — 12.0; 13.0 units on a scale — p=0.49

Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants

Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…

Primary: Proportion of Surgical Plans Recorded Prior to the SPSI Report That Are Altered After Integration of SPSI Into the Surgical Planning — 47; 22; 6 Surgical plans

Primary: Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 4.5 Months — 1785.42; 1819.41; 1805.52; 1834.67 μm

Primary: Proportion of Participants With New Vertebral Fractures — 28; 64 Participants (with at least one event) — p=0.000094

Primary: Oswestry Disability Index (ODI) at 12 Weeks — 35.95; 33.54; 37.83 units on a scale

Primary: Change in Areal Bone Mineral Density at Hip — 0.92; -12.0; 1.19; -12.9 percentage change

Primary: Bone Mineral Density BMD of the Total Hip as Assessed by DXA. — 0.66; 0.63; 0.64; 0.65 g/cm^2 — p=0.84

Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline

Primary: Posttreatment Pain — 5.3; 6.2; 4.2; 5.6 scores on a scale

Primary: Feasibility of Recruitment and Retention — 66; 64 Participants

Primary: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint — 206; 193; 142; 143 participants — p=0.642

Primary: Percent Change in Bone Mass Density (BMD) in the Hip — -2.21; -12.82 percent change in bone mass density — p=0.05

Primary: Post-operative Pain Within 6 Months After Iliosacral Screw Removal Using the Brief Pain Inventory (BPI) — 3.7; 4.7 units on a scale — p==0.57

Primary: BMD of Total Hip by DXA — 1.32 Percent change

Primary: Fusion Rates Per Level Using the Bridwell Interbody Grading Scale — 64; 50 Fusions

Primary: Bone Mineral Density — 184.0; 174.9; 188.5 g/cm^3

Primary: Initial Symptom Control — 3; 28; 3; 27 Participants

Primary: Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo — 3.6; 10.3; 7.2 Vertebral fractures — p=0.0001

Primary: Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12. — 1.102; 1.134; 0.898; 1.038 g/cm2

Primary: Number of Participants With Evidence of Cortical Bridging for Fracture Healing — 9; 8 Participants

Primary: Radiologic Evidence of Bone Healing — 12.6; 11.2; 15.4; 13.2 units on a scale

Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 87; 86 percentage of participants

Primary: Toxicity — 14; 0; 0; 0 participants

Primary: Number of Subjects With Successful Radiographic Fusion — 90 Participants

Primary: Quality of Spine Fusion, Measured by the Number of Participants With Complete Spine Fusion at 1 Year — 11; 6 Participants

Primary: Revision Surgery — 107; 117 Participants

Primary: Cervical Spine Injury — 274; 159 Participants — p=.05

Primary: Number of Participants With Radiographic Analysis of Evidence of Fracture or Healing Based on CT Scan — 8 Participants